Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating how the study medicine PF-06823859 dazukibart works in adults with active idiopathic inflammatory myopathies, specifically dermatomyositis DM and polymyositis PM. These rare diseases cause muscle inflammation leading to muscle weakness and sometimes skin rash in DM. The study aims to assess the safety and effectiveness of dazukibart compared to placebo in people already receiving stable doses of corticosteroids or immunosuppressants. Participants will be randomly assigned to receive either dazukibart or a placebo via intravenous infusion every 4 weeks, starting from Day 1 to Week 48. Each infusion takes about 1 hour and is administered at the study site. The study uses a double-blind design, meaning neither participants nor researchers know who receives the active drug or placebo, allowing for an unbiased comparison. Participants will be involved in approximately 15 visits over about 13 months. During these visits, researchers will monitor muscle strength, skin symptoms, physical function, fatigue, itch severity, corticosteroid use, and overall improvement using various clinical scales and patient questionnaires. Safety will be closely followed throughout the study. The main outcome measure is the Total Improvement Score TIS evaluated at 24 weeks outside the US and 52 weeks within the US.